Driven by science, focused on people.

ABCL635 is a potential first-in-class antibody medicine for the non-hormonal treatment of VMS (commonly known as hot flashes) associated with menopause. ABCL635 specifically targets NK3R, a clinically validated complex membrane protein found on KNDy neurons in the infundibular nucleus of the hypothalamus that helps regulate body temperature. ABCL635 is the first AbCellera-led program generated using our GPCR and ion channel technologies. It is currently being studied in a phase 1 trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and the frequency and severity of VMS with subcutaneous doses of ABCL635.

ABCL575 is an investigative monoclonal antibody for the treatment of moderate-to-severe atopic dermatitis (AD), with potential applications to other inflammatory and autoimmune conditions. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. It has been engineered with a modified Fc domain to support Fc-silencing and half-life extension. In preclinical studies, ABCL575 shows potent inhibition of T cell-mediated inflammatory pathways, favorable tolerability, and an in vivo half-life that is expected to support less frequent dosing than current clinical-stage molecules. A phase 1 clinical trial was initiated in Q3 of 2025 to assess safety and tolerability in healthy participants following subcutaneous doses of ABCL575.

ABCL688 is a potential antibody medicine targeting a multipass complex membrane protein for the treatment of an undisclosed indication in autoimmunity. ABCL688 is the second AbCellera-led program generated using our GPCR and ion channel technologies, and the program entered IND-enabling studies in Q2 of 2025.